COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advance proteome and proteogenome science and technology development through community resources (data and reagent), and accelerate the translation of molecular findings into the clinic. This is achieved through OCCPR-supported programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, and collaborations with international organizations/institutions.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

GBM Discovery Data Available on the PDC

Glioblastoma Multiforme Discovery Study proteomic and phosphoproteomic data previously available only on thte CPTAC Data Portal is now available on the Proteomic Data Commons.  


CPTAC Radiology Data Release Through TCIA

TCIA has released its quarterly update for CPTAC radiology data with 44 new radiology cases!  These cases span cutaneous melanoma, glioblastoma multiforme, head & neck squamous cell carcinoma, lung squamous cell carcinoma, lung adenocarcinoma, pancreatic ductal adenocarcinoma and sarcoma tumor tissue types.  In addition, the TCIA monthly histopathology report lists the addition of 10 new pathology slides


OCCPR Webinar: NCI's Antibody Program

Antibodies are among the most commonly used tools in the biological sciences - put to work in many experiments to identify and isolate other molecules.  NCI’s Antibody Program has developed more than 500 available antibodies that have been designed and optimized, with the vast majority developed as fit-for-purpose reagents.


CPTAC Glioblastoma Multiforme (GBM) Discovery Study Data Release

Proteomic and phosphoproteomic data for the CPTAC Glioblastoma Discovery Study is now available on the CPTAC Data Portal. 


Even More CPTAC Pathology Images Available!

...And there's more!!!  Another new batch of CPTAC histopathology imaging data has been released and is now publicly available on the TCIA CPTAC Pathology Portal.


CPTAC Researchers Associate High Immune Checkpoint Components and Immune Tolerance with Poor Clinical Outcomes in Luminal B Breast Cancer

As part of NIH’s mission for collaboration and team science, Dr. Matthew Ellis, Co-Principal Investigator of the CPTAC Proteogenomic Translational Research Center and Dr.


OCCPR Webinar: Proteomic Assay Portal

Did you know about NCI’s Proteomic (CPTAC) Assay Portal?  It’s a free resource for biological scientists performing mass spectroscopy.  The portal houses more than 2300 fit-for-purpose, proteomic assays designed and optimized for anyone to use.   Each assay is validated using CPTAC experimental g


The CPTAC Pathology Portal Has New Images

A new batch of CPTAC histopathology imaging data has been released and is now publicly available on the TCIA CPTAC Pathology Portal.

The TCIA quarterly report lists the addition of 76 new pathology slides and 25 new pathology subjects for the cutaneous melanoma, glioblastoma multiforme, and sarcoma tumor types.

TCIA has partnered with CPTAC to host both the radiology and pathology imaging data generated by the CPTAC Program.  Imaging data is available for 10 cancer types including AML, clear cell renal cell carcinoma, head & neck squamous cell carcinoma, lung squamous...


GDC Releases Harmonized Genomic Data From CPTAC

Data Release-20 from the Genomic Data Commons (GDC) includes genomics from a new CPTAC project!  

The CPTAC Proteogenomic Confirmatory Study examined prospectively collected colon, breast and ovarian tumors for analysis, including harmonized whole exome sequencing, RNA-Seq, and miRNA-Seq that is now available.  Complimentary proteomic and phosphoproteomic analysis can also be found on the CPTAC Data Portal and the Proteomic Data Commons (PDC).

CPTAC has provided the Genomic Data Commons (GDC) with genomic data from over 600 cancer patients with diverse disease types including...


Pages